Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunomodulation of asthma: where do we stand?

× No keyword cloud information.

13 in total

1. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.

Authors: T B Casale; I L Bernstein; W W Busse; C F LaForce; D G Tinkelman; R R Stoltz; R J Dockhorn; J Reimann; J Q Su; R B Fick; D C Adelman
Journal: J Allergy Clin Immunol Date: 1997-07 Impact factor: 10.793

2. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator.

Authors: H Shirota; K Sano; T Kikuchi; G Tamura; K Shirato
Journal: J Immunol Date: 2000-06-01 Impact factor: 5.422

3. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects.

Authors: J V Fahy; H E Fleming; H H Wong; J T Liu; J Q Su; J Reimann; R B Fick; H A Boushey
Journal: Am J Respir Crit Care Med Date: 1997-06 Impact factor: 21.405

4. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production.

Authors: T S Kim; R H DeKruyff; R Rupper; H T Maecker; S Levy; D T Umetsu
Journal: J Immunol Date: 1997-05-01 Impact factor: 5.422

5. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

Authors: Christian Möller; Sten Dreborg; Hosne A Ferdousi; Susanne Halken; Arne Høst; Lars Jacobsen; Antti Koivikko; Dieter Y Koller; Bodo Niggemann; Lene A Norberg; Radvan Urbanek; Erkka Valovirta; Ulrich Wahn
Journal: J Allergy Clin Immunol Date: 2002-02 Impact factor: 10.793

6. Long-term clinical efficacy of grass-pollen immunotherapy.

Authors: S R Durham; S M Walker; E M Varga; M R Jacobson; F O'Brien; W Noble; S J Till; Q A Hamid; K T Nouri-Aria
Journal: N Engl J Med Date: 1999-08-12 Impact factor: 91.245

7. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

Authors: S A Bryan; B J O'Connor; S Matti; M J Leckie; V Kanabar; J Khan; S J Warrington; L Renzetti; A Rames; J A Bock; M J Boyce; T T Hansel; S T Holgate; P J Barnes
Journal: Lancet Date: 2000 Dec 23-30 Impact factor: 79.321

8. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma.

Authors: L C Borish; H S Nelson; J Corren; G Bensch; W W Busse; J B Whitmore; J M Agosti
Journal: J Allergy Clin Immunol Date: 2001-06 Impact factor: 10.793

9. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season.

Authors: D R Wilson; K T Nouri-Aria; S M Walker; G B Pajno; F O'Brien; M R Jacobson; I S Mackay; S R Durham
Journal: J Allergy Clin Immunol Date: 2001-06 Impact factor: 10.793

10. Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL-4 receptor.

Authors: H Renz; K Bradley; K Enssle; J E Loader; G L Larsen; E W Gelfand
Journal: Int Arch Allergy Immunol Date: 1996-02 Impact factor: 2.749